PMN Stock Analysis: Buy, Sell, or Hold?
PMN - ProMIS Neurosciences Inc. Common Shares (ON)
$13.16
2.41 (22.42%)
▲
5d:
+23.11%
30d:
+21.74%
90d:
+2.17%
WAIT
LOW Confidence
Analysis Updated: Jun 30, 2026 12:00 AM ET
Earnings: Aug 12, 2026
Get Alerted When PMN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: PMN is 18.5% above its trading range ($11.11). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: PMN is 18.5% above its trading range ($11.11). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: PMN is currently trading at $13.16, which is considered extended relative to its 30-day fair value range of $9.71 to $11.11.
Technical Outlook: Technically, PMN is in a downtrend. The price is approaching resistance at $11.37. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 22.4% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $34.39 (+161.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PMN is in a downtrend. The price is approaching resistance at $11.37. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 22.4% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $34.39 (+161.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$9.71 -
$11.11
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
45.8%
All Signals
- BEARISH: Price significantly overextended (+18.5% above its trading range)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+22.4%)
- BULLISH: Trading 161.4% below Wall St target ($34.39)
- WARNING: Recommendation downgraded due to 18.5% overvaluation
Trading Range Analysis
30-Day Trading Range
$9.71 -
$11.11
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$9.09
Resistance Level
$11.37
Current Trend
Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.51
Wall Street Target
$34.39
(+161.4%)
Share & Embed Analysis
Last updated: June 30, 2026 10:52 PM ET
Data refreshes hourly during market hours. Next update: 11:52 PM
Data refreshes hourly during market hours. Next update: 11:52 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PMN showing a specific setup today?
Insider Activity (6 Months)
5
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Patrick D Kirwin
BUY
4000 shares
2026-04-22
Eugene Williams
BUY
2000 shares
2026-03-04
Eugene Williams
BUY
1000 shares
2026-03-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$276 | 60 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 58 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 58 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$83 | 61 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$110 | 64 BUY |
